Enhanced Permeability and Retention Effect in Relation to Tumor Targeting

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 1, Issue , 2011, Pages 65-84

  Maeda, Hiroshi ^a  

^a NONE

Author keywords

Angiotensin induced hypertension; Difficult to treat cancer; EPR effect; Heterogeneity; Metastatic liver cancer; Nitric oxide; Permeability factor; SMANCS Lipiodol ; Tumor selective delivery

Indexed keywords

EID: 84869501324     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch3     Document Type: Chapter

References (57)

1. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 46, 6387-6392.
2. Maeda, H., Matsumoto, T., Konno, T., Iwai, K., and Ueda, M. (1984) Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J. Protein Chem., 3, 181-193.
3. Maeda, H., Matsumura, Y., Oda, T., and Sasamoto, K. (1986) Calicheamicin antibody-drug conjugates and beyond in Protein Tailoring for Food and Medical Uses (eds R.E. Feeney and J.R. Whitaker), Dekker, New York, pp. 353-382.
4. Oda, T., Akaike, T., Hamamoto, T., and Maeda, H. (1989) Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science, 244, 974-976.
5. Ogino, T., Inoue, M., Ando, Y., Awai, M., Maeda, H., and Morino, Y. (1988) Chemical modification of superoxide dismutase. Int. J. Pept. Protein Res., 32, 153-159.
6. Maeda, H., Takeshita, J., and Yamashita, A. (1980) Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. Eur. J. Cancer, 16, 723-731.
7. Maeda, H., and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst., 6, 193-210.
8. Maeda H., Takeshita, J., Kanamaru, R., Sato, H., Khatoh, J., and Sato, H. (1979) Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent- and water-soluble polymer-conjugated protein. Gann, 70, 601-606.
9. Takeshita, J., Maeda, H., and Kanamaru, R. (1982) In vitro mode of action, pharmacokinetics, and organ specificity of poly(maleic acid-styrene)-conjugated neocarzinostatin, SMANCS. Gann, 73, 278-284.
10. Maeda, H., Takeshita, J., and Kanamaru, R. (1979) A lipophilic derivative of neocarzinostatin: a polymer conjugation of an antitumor protein antibiotic. Int. J. Pept. Protein Res., 14, 81-87.
11. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., and Maeda, H. (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89, 307-314.
12. Seymour, L.W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., and Duncan, R. (1995) Influence of molecular weight on passive tumour accumulation of a soluble macromolecular durg carrier. Eur. J. Cancer, 31, 766-770.
13. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J. Control. Release, 65, 271-284.
14. Maeda, H. (1991) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev., 6, 181-202.
15. Maeda, H., Sawa, T., and Konno, T. (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release, 74, 47-61.
16. Fang, J., Nakamura, H., and Maeda, H. (2010) EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitation and augmentation of the effect. Adv. Drug Deliv. Rev., 63, 136-151.
17. Maeda, H. (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Adv. Enzyme Regul., 41, 189-207.
18. Maeda, H. (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem., 21, 797-802.
19. Maeda, H., Noguchi, Y., Sato, K., and Akaike, T. (1994) Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res., 85, 331-334.
20. Wu, J., Akaike, T., and Maeda, H. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res., 58, 159-165.
21. Maeda, H., Matsumura, Y., and Kato, H. (1988) Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem., 263, 16051-16054.
22. Konerding, M.A., Miodonski, A.J., and Lametschwandtner, A. (1995) Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc., 9, 1233-1244.
23. Kratz, F., Müller, I.A., Ryppa, C., and Warnecke, A. (2008) Prodrug strategies in anticancer chemotherapy. Chem. Med. Chem., 3, 20-53.
24. Iwai, K., Maeda, H., and Konno, T. (1984) Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res., 44, 2115-2121.
25. Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M., and Miyauchi, Y. (1984) Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer, 54, 2367-2374.
26. Maki, S., Konno, T., and Maeda, H. (1985) Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer, 56, 751-757.
27. Nagamitsu, A., Greish, K., and Maeda, H. (2009) Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol., 39, 756-766.
28. Matsumoto, K., Yamamoto, T., Kamata, R., and Maeda, H. (1984) Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J. Biochem., 96, 739-749.
29. Maeda, H., Wu, J., Okamoto, T., Maruo, K., and Akaike, T. (1999) Kallikrein-kinin in infection and cancer. Immunopharmacology, 43, 115-128.
30. Maeda, H. (2002) in The Encyclopedia of Molecular Medicine, vol. 4 (ed. T.E. Creighton), John Wiley & Sons, Inc., New York, pp. 2663-2668.
31. Maruo, K., Akaike, T., Inada, Y., Ohkubo, I., Ono, T., and Maeda, H. (1993) EPR effect of microbial and mita protease on low and high molecular weight kininogen. J. Biol. Chem., 268, 17711-17715.
32. Matsumura, Y., Kimura, M., Yamamoto, T., and Maeda, H. (1988) Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res., 79, 1327-1334.
33. Wu, J., Akaike, T., Hayashida, K., Okamoto, T., Okuyama, A., and Maeda, H. (2001) Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinase. Jpn. J. Cancer Res., 92, 439-451.
34. Sawa, T., Akaike, T., and Maeda, H. (2000) Tyrosine nitration by peroxynitrite formed from nitric oxide and superoxide generated by xanthine oxidase. J. Biol. Chem., 275, 32467-32474.
35. Akaike, T., Okamoto, S., Sawa, T., Yoshitake, J., Tamura, F., Ichimori, K., Miyazaki, K., Sasamoto, K., and Maeda, H. (2003) 8-Nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc. Natl. Acad. Sci. USA, 100, 685-690.
36. Maeda, H., Sawa, T., Yubisui, T., and Akaike, T. (1999) Free radical generation from heterocyclic amines by cytochrome b5 reductase in the presence of NADH. Cancer Lett., 143, 117-121.
37. Sawa, T., Akaike, T., Ichimori, K., Akuta, T., Kaneko, K., Nakamura, H., Stuehr, D.J., and Maeda, H. (2003) Superoxide generation mediate by 8-nitroguanosine, a highly redox active nucleic acid derivative. Biochem. Biophys. Res. Commun., 311, 300-306.
38. Daruwalla, J., Nikfarjam, M., Greish, K., Malcontenti-WilsonI, C., Muralidharan, V., Christophe, C., and Maeda, H. (2010) In vitro and in vivo evaluation of tumor targeting SMA-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci., 101, 1866-1874.
39. Suzuki, M., Hori, H., Abe, I., Saito, S., and Sato, H. (1984) Functional characterization of the microcirculation in tumors. Cancer Metastasis Rev., 3, 115-126.
40. Suzuki, M., Hori, K., Abe, I., Saito, S., and Sato, H. (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst., 67, 663-669.
41. Li, C.J., Miyamoto, Y., Kojima, Y., and Maeda, H. (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer, 67, 975-980.
42. Seki, T., Fang, J., and Maeda, H. (2009) Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci., 100, 2426-2430.
43. Maeda, H. (2010) Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect. J. Control. Release, 142, 296-298.
44. Yasuda, H., Nakayama, K., Watanabe, M., Suzuki, S., Fuji, H., Okinaga, S., Kanda, A., Zayasu, K., Sasaki, T., Asada, M., Suzuki, T., Yoshida, M., Yamada, S., Inoue, D., Kaneta, T., Kondo, T., Takai, Y., Sasaki, H., Yanagihara, K., and Yamaya M. (2006) Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin. Cancer Res., 12, 6748-6757.
45. YasudaH., Yanagihara, K., Nakayama, Mio, T., Sasaki, T., Asada, M., Yamaya, M., and Fukushima, M. (2010) in Nitric Oxide and Cancer (ed. B. Bonavida), Springer, New York, pp. 419-442.
46. Siemens, D.R., Heaton, J., Adams, M., Kawakami, J., and Graham, C. (2009) Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology, 74, 878-883.
47. Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., Tsurumi, H., Takashina, K., and Maeda H. (1992) Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn. J. Cancer Res., 83, 240-243.
48. Tanaka, S., Akaike, T., Wu, J., Fang, J., Sawa, T., Ogawa, M., Beppu, T., and Maeda, H. (2003) Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin I2 analogue beraprost sodium. J. Drug Target., 11, 45-52.
49. Fang, J., Qin, H., Nakamura, H., Tsukigawa, K., and Maeda, H. (2011) Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention (EPR) effect of solid tumor. (Submitted)
50. Doi, K., Akaike, T., Fujii, S., Horie, H., Noguchi, Y., Fujii, S., Beppu, T., Ogawa, M., and Maeda, H. (1999) Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br. J. Cancer, 80, 1945-1954.
51. Fang, J., Sawa, T., Akaike, T., and Maeda, H. (2002) Tumor-targeted delivery of polyethylene glycol-conjugated d-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res., 62, 3138-3143.
52. Fang, J., Sawa, T., Akaike, T., Akuta, T., Greish, K., Hamada, A., and Maeda, H. (2003) In vivo, antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res., 63, 3567-3574.
53. Hatakeyama, H., Akita, H., and Harashima, H. (2011) A multifunctional envelope type nano device (MEND) for drug and gene delivery to tumors based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug. Deliv. Rev., 63, 152-160.
54. Law, B., and Tung, C.H. (2009) Proteolysis: a biological process adapted in drug delivery, therapy, and imaging. Bioconjug. Chem., 20, 1683-1695.
55. Tsukigawa, K., Nakamura, H., Fang, J., and Maeda, H. (2010) Annual Meeting of Controlled Release Society, Portland, OR, abstract 24.
56. Nakamura, H., Fang, J., Bharate, G., Tsukigawa, K., and Maeda, H. (2011) Intracellular uptake and behaviour of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; Unique intracellular disintegration of SMA micelles. J. Control. Release, in press.
57. Ishida, T., Ichihara, M., Wang, X.Y., Yamamoto, K., Kimura, J., Majima, E., and Kiwada, H. (2006) Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release, 112, 15-25.